KR102681027B1 - Cns 부종과 관련한 손상 또는 병태의 치료 방법 - Google Patents

Cns 부종과 관련한 손상 또는 병태의 치료 방법 Download PDF

Info

Publication number
KR102681027B1
KR102681027B1 KR1020187012950A KR20187012950A KR102681027B1 KR 102681027 B1 KR102681027 B1 KR 102681027B1 KR 1020187012950 A KR1020187012950 A KR 1020187012950A KR 20187012950 A KR20187012950 A KR 20187012950A KR 102681027 B1 KR102681027 B1 KR 102681027B1
Authority
KR
South Korea
Prior art keywords
delete delete
hours
subject
sur1
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187012950A
Other languages
English (en)
Korean (ko)
Other versions
KR20180063296A (ko
Inventor
스벤 마틴 제이콥슨
Original Assignee
레메디 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레메디 파마슈티칼즈, 인크. filed Critical 레메디 파마슈티칼즈, 인크.
Priority to KR1020247021781A priority Critical patent/KR20240105519A/ko
Publication of KR20180063296A publication Critical patent/KR20180063296A/ko
Application granted granted Critical
Publication of KR102681027B1 publication Critical patent/KR102681027B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187012950A 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법 Active KR102681027B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247021781A KR20240105519A (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021781A Division KR20240105519A (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Publications (2)

Publication Number Publication Date
KR20180063296A KR20180063296A (ko) 2018-06-11
KR102681027B1 true KR102681027B1 (ko) 2024-07-02

Family

ID=58488580

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187012950A Active KR102681027B1 (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법
KR1020247021781A Ceased KR20240105519A (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247021781A Ceased KR20240105519A (ko) 2015-10-07 2016-10-07 Cns 부종과 관련한 손상 또는 병태의 치료 방법

Country Status (15)

Country Link
US (4) US20180280325A1 (https=)
EP (1) EP3359162B1 (https=)
JP (4) JP7349786B2 (https=)
KR (2) KR102681027B1 (https=)
CN (2) CN108348534A (https=)
AU (3) AU2016335767B2 (https=)
BR (1) BR112018006925A2 (https=)
CA (1) CA3001321A1 (https=)
EA (1) EA201890893A1 (https=)
ES (1) ES2940669T3 (https=)
HK (1) HK1257542A1 (https=)
IL (1) IL258509B2 (https=)
MA (1) MA45574A (https=)
MX (1) MX392466B (https=)
WO (1) WO2017062765A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
MA55813A (fr) * 2019-05-02 2022-03-09 Biogen Chesapeake Llc Procédé de traitement de sujets souffrant de contusions du système nerveux central
CN120004770A (zh) * 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) * 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurocrit Care (2014) 21:43-51.*

Also Published As

Publication number Publication date
JP7810762B2 (ja) 2026-02-03
AU2022279369B2 (en) 2025-02-13
KR20180063296A (ko) 2018-06-11
IL258509B2 (en) 2023-04-01
CN108348534A (zh) 2018-07-31
EA201890893A1 (ru) 2018-09-28
EP3359162A4 (en) 2019-08-28
US20240216309A1 (en) 2024-07-04
JP2023053274A (ja) 2023-04-12
KR20240105519A (ko) 2024-07-05
JP2018530564A (ja) 2018-10-18
BR112018006925A2 (pt) 2018-10-16
MA45574A (fr) 2019-05-15
JP2024164167A (ja) 2024-11-26
MX2018004286A (es) 2018-08-09
MX392466B (es) 2025-03-24
US11951085B2 (en) 2024-04-09
AU2016335767B2 (en) 2022-10-06
US20220125750A1 (en) 2022-04-28
WO2017062765A1 (en) 2017-04-13
AU2025202620A1 (en) 2025-05-01
CN115737816A (zh) 2023-03-07
ES2940669T3 (es) 2023-05-10
AU2016335767A1 (en) 2018-05-24
AU2016335767A8 (en) 2018-06-28
AU2022279369A1 (en) 2023-01-19
HK1257542A1 (zh) 2019-10-25
JP7592768B2 (ja) 2024-12-02
US20180280325A1 (en) 2018-10-04
EP3359162A1 (en) 2018-08-15
JP2021073317A (ja) 2021-05-13
CA3001321A1 (en) 2017-04-13
JP7349786B2 (ja) 2023-09-25
IL258509B (en) 2022-12-01
US20250017880A1 (en) 2025-01-16
EP3359162B1 (en) 2022-12-21
IL258509A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
KR102681027B1 (ko) Cns 부종과 관련한 손상 또는 병태의 치료 방법
US12251389B1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
JP2018530564A5 (https=)
US12251388B1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
JP2026069546A (ja) Ｃｎｓ浮腫に関連する損傷または状態を処置する方法
JP2022531312A (ja) 中枢神経系挫傷に苦しむ対象の治療方法
US20260115210A1 (en) Method for treating subjects suffering from central nervous system contusions
May et al. Treatment of elevated intracranial pressure
US12611416B2 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US20250325564A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
AbdelRady et al. Role of Granisetron in preventing hypotension after spinal anaesthesia with Levobupivacaine in rheumatic patients undergoing elective cesarean section: A randomized controlled trial
WO2025212154A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Kla Best Practice & Research Clinical Anaesthesiology

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211001

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231001

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240401

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240628

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240628

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240628

End annual number: 3

Start annual number: 1

PG1601 Publication of registration